Gluten Related Disorders in Barrett's Esophagus

NCT ID: NCT03329534

Last Updated: 2018-03-21

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-04-01
• Study Completion Date: 2018-12-30

Brief Summary

In a small group of people gluten, a storage protein commonly in wheat and other grains, can cause gut inflammation and symptoms like diarrhea and abdominal pain. Gluten-related disorders include celiac disease (CD) and non-celiac gluten sensitivity (NCGS) and are treated by starting a gluten free diet (GFD). Patients with CD and NCGS also more commonly experience esophageal reflux and damage to the lining of the esophagus. A potential consequence of long-standing heartburn is Barrett's esophagus (BE), a major risk factor for cancer of the esophagus.

This study aims to investigate the mechanism that leads to reflux and BE in those with gluten related disorders, and to assess if a GFD is beneficial. We will study the upper gut function and reflux activity in patients with BE both with and without a GRD disorder. Testing will occur before and after a gluten free diet is instituted. The results will help inform health care providers and patients about the connection between gluten-related disorders, reflux, BE, and the role of GFD.

Detailed Description

Perhaps patient's with gluten related disorders develop Barrett's esophagus due to non-acid reflux precipitated by upper gastrointestinal motility changes that respond to a gluten free diet; whereas patients without gluten related disorders develop Barrett's due to the accepted mechanism of acid reflux.

The primary objectives are to explore if patients with gluten-related disorders (CD and GS) may have an altered mechanism of developing Barrett's esophagus typified by increased alkali reflux compared to those without gluten-related disorders; and to determine if this mechanism (altered motility and increased non-acid reflux) responds to a gluten free diet.

Specific objectives include assessing whether patients with GRD and Barrett's esophagus have altered esophageal reflux extent, frequency, and type (assessed by pH-impedance); altered symptom profiles; differential esophageal body and sphincter pressures (assessed by manometry); aberrant gastroduodenal motility (assessed by videofluoroscopy) in comparison to patients with BE and no GRD. Finally a gluten free diet will be instituted to assess whether a gluten-free diet alters esophageal reflux extent, frequency, and type or symptom profiles in those with BE with and without a GRD.

Conditions

Celiac Disease; Barrett Esophagus; Gluten Sensitivity; GERD

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Subjects with GRDs

An intervention of a change in diet, specifically a gluten free diet taught by a health care professional will be administered for one month's time.

Group Type: EXPERIMENTAL

Gluten free diet

Intervention Type: OTHER

A month long gluten free diet

Subjects without GRDs

An intervention of a change in diet, specifically a gluten free diet taught by a health-care professional will be administered for one month's time.

Group Type: ACTIVE_COMPARATOR

Gluten free diet

Intervention Type: OTHER

A month long gluten free diet

Interventions

Gluten free diet

A month long gluten free diet

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Aged 18 years and over
• Barrett's Esophagus diagnosis based on endoscopy and esophageal biopsies
• Patients able to comply to the study procedures, according to the investigator's own judgment

Exclusion Criteria

• Patients who have been on a gluten free diet within the last six months
• History of bariatric surgery, fundoplication, or gastrectomy (partial or complete)
• Connective tissue disease
• Concurrent organic GI pathology other than benign polyps, haemorrhoids, lipomas, H. pylori infection, diverticulosis, and melanosis coli
• Chronic treatment with high dose opioids
• Alcohol or drug abuse
• Pregnant or breastfeeding women. Women enrolling in the study will be advised to avoid pregnancy during the course of the study by using adequate birth control such as abstinence, oral contraceptive pill, barrier contraceptives (i.e condom). If a subject becomes pregnant she will be withdrawn from the study.
• Concurrent systemic disease and/or laboratory abnormalities considered by investigators to be a risk or that could interfere with data collection

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

McMaster University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Premysl Bercik, MD

Role: STUDY_DIRECTOR

McMaster University

Central Contacts

Premysl Bercik, MD

Role: CONTACT

bercikp@mcmaster.ca

905 521 2100 ext. 73495

Other Identifiers

GRD in BE

Identifier Type: -

Identifier Source: org_study_id